Acute Myeloid Leukemia Clinical Trial
— LAM-SA 2007Official title:
Randomized Prospective Study of Adding Lomustine to Idarubicin and Cytarabine for Induction and Post-remission Chemotherapy in Older Patients With Acute Myeloid Leukaemia, and Feasibility of Allogeneic Transplantation for Patients From 60 to 65 Years Old
A multicenter randomized trial comparing induction therapy (IC: Idarubicin and Cytarabine, 5 + 7) to ICL (the same drugs plus lomustine (CCNU), 200 mg/m2 orally at day 1). Patients in complete remission (CR) will then receive a post-remission schedule with or without lomustine according to randomization. Patients from 60 to 65 years old will be proposed to reduced conditioning allogeneic transplantation after first consolidation.
Status | Completed |
Enrollment | 459 |
Est. completion date | December 2013 |
Est. primary completion date | December 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 60 Years and older |
Eligibility |
Inclusion Criteria: - Patients aged 60 years and older with de novo AML and non-poor cytogenetic features. - Patients with no unfavourable cytogenetic (based on GOELAMS-BGMT criteria) - Performance status and Sorror score < 3 . - Signed and dated informed consent. Exclusion Criteria: - Acute promyelocytic leukemia. - Patients with myeloproliferative syndromes prior to diagnosis of AML. - Patients who previously had myelodysplastic syndrome. - Positive serology for HIV. - Patients with unfavourable cytogenetic - Patients with an isolated medullary extra localization of their disease |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
France | Services maladies du sang, cancérologie, Hôpital Sud, CHU Amiens | Amiens | |
France | Service des maladies du sang, Centre Hospitalier Universitaire d'Angers | Angers | |
France | Service Hématologie, Centre Hospitalier Annecy | Annecy | |
France | C.H Victor Dupouy | Argenteuil | |
France | Service Médecine Interne, Onco-Hématologie, Maladies Infectieuses, Hôpital Henri Duffaut, Centre Hospitalier Avignon | Avignon | |
France | Service Hématologie, Centre Hospitalier de la Côte Basque | Bayonne | |
France | Service Hématologie, Hôpital Minjoz | Besançon | |
France | Unité Hématologie, Centre Hospitalier Blois | Blois | |
France | Service des maladies du sang - Hôpital Haut-Lévêque | Bordeaux - Pessac | |
France | Service Hématologie, Hôpital Dr Duchenne | Boulogne-sur-Mer | |
France | Service Hématologie, Hôpital Augustin Morvan | Brest | |
France | Service Hématologie et Thérapie cellulaire, Pavillon Villemin Pasteur, CHU Clermont-Ferrand | Clermont-Ferrand | |
France | Service Oncologie - Hématologie, Hôpital Pasteur, Centre Hospitalier Colmar | Colmar | |
France | Service Hématologie Clinique, CHU Dijon Hôpital des enfants | Dijon | |
France | Service Hématologie Clinique, Hôpital Michallon, CHU de Grenoble | Grenoble | |
France | Service Onco-Hématologie 3, Institut Paoli Calmettes | Marseille | |
France | Service Hématologie Oncologie, CHR Metz-Thionville | Metz | |
France | Service Hématologie Oncologie, Hôpital Lapeyronie, CHU de Montpellier | Montpellier | |
France | Département d'hématologie, Hôpital E.Muller, Centre Hospitalier de Mulhouse | Mulhouse | |
France | Service Hématologie Clinique, CHU -Hôtel Dieu | Nantes | |
France | Service Hématologie Clinique, Hôpital Archet 1 | Nice | |
France | Service Médecine B - Unité Onco-hématologique, CHU Caremeau | Nîmes | |
France | Service Oncologie Médicale, Hôpital de la Source | Orléans | |
France | Unité d'Hématologie, Hôpital Cochin | Paris | |
France | Service Hématologie, CHG Saint Jean | Perpignan | |
France | Service Hématologie Clinique, Hôpital Robert Debre | Reims | |
France | Service Hématologie Clinique, Hôpital Pontchaillou | Rennes | |
France | Service d'Hématologie, Institut de Cancérologhie de la Loire | Saint Priez en Jarez | |
France | Département d'Hématologie et d'Oncologie, Hôpital CHRU de Hautepierre | Strasbourg | |
France | Service Hématologie, Hôpital Purpan | Toulouse | |
France | Service Hématologie Clinique, Hôpital Bretonneau | Tours | |
France | Service Hématologie - Médecine Interne, Hôpitaux de Brabois | Vandoeuvre-les-Nancy |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Bordeaux |
France,
Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, Anderson JE, Petersdorf SH. Age and acute myeloid leukemia. Blood. 2006 May 1;107(9):3481-5. Epub 2006 Feb 2. — View Citation
Gardin C, Turlure P, Fagot T, Thomas X, Terre C, Contentin N, Raffoux E, de Botton S, Pautas C, Reman O, Bourhis JH, Fenaux P, Castaigne S, Michallet M, Preudhomme C, de Revel T, Bordessoule D, Dombret H. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood. 2007 Jun 15;109(12):5129-35. Epub 2007 Mar 6. — View Citation
Hegenbart U, Niederwieser D, Sandmaier BM, Maris MB, Shizuru JA, Greinix H, Cordonnier C, Rio B, Gratwohl A, Lange T, Al-Ali H, Storer B, Maloney D, McSweeney P, Chauncey T, Agura E, Bruno B, Maziarz RT, Petersen F, Storb R. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol. 2006 Jan 20;24(3):444-53. Epub 2005 Dec 12. — View Citation
Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E 3rd. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994 Oct 6;331(14):896-903. — View Citation
Pigneux A, Perreau V, Jourdan E, Vey N, Dastugue N, Huguet F, Sotto JJ, Salmi LR, Ifrah N, Reiffers J. Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial results. Haematologica. 2007 Oct;92(10):1327-34. — View Citation
Sekeres MA, Stone R. Older adults with acute myeloid leukemia. Curr Oncol Rep. 2002 Sep;4(5):403-9. Review. — View Citation
Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman P, Lee EJ, Moore JO, Powell BL, Schiffer CA. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med. 1995 Jun 22;332(25):1671-7. — View Citation
Takagi K. [Neurophysiological and clinical aspects of autonomic centers: introduction]. Nihon Seirigaku Zasshi. 1972 May;34(5):257-61. Japanese. — View Citation
Witz F, Sadoun A, Perrin MC, Berthou C, Brière J, Cahn JY, Lioure B, Witz B, François S, Desablens B, Pignon B, Le Prisé PY, Audhuy B, Caillot D, Casassus P, Delain M, Christian B, Tellier Z, Polin V, Hurteloup P, Harousseau JL. A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM). Blood. 1998 Apr 15;91(8):2722-30. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall Survival | 1 year | Yes | |
Secondary | Complete remission | 1 year | Yes | |
Secondary | Event-free survival | 1 year | Yes | |
Secondary | Prognostic factors | 1 year | Yes | |
Secondary | Quality of Life (QOL) | 1 year | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Recruiting |
NCT04460235 -
Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma
|
Phase 4 | |
Completed |
NCT03678493 -
A Study of FMT in Patients With AML Allo HSCT in Recipients
|
Phase 2 | |
Completed |
NCT04022785 -
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
Recruiting |
NCT05424562 -
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
|
||
Terminated |
NCT03224819 -
Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)
|
Early Phase 1 | |
Completed |
NCT03197714 -
Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Active, not recruiting |
NCT04070768 -
Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113
|
Phase 1 | |
Active, not recruiting |
NCT04107727 -
Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)
|
Phase 2 | |
Recruiting |
NCT04385290 -
Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04920500 -
Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients
|
N/A | |
Recruiting |
NCT03897127 -
Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
|
Phase 3 | |
Active, not recruiting |
NCT04021368 -
RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
|
Phase 1 | |
Recruiting |
NCT03665480 -
The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML
|
Phase 2/Phase 3 | |
Completed |
NCT02485535 -
Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant
|
Phase 1 | |
Enrolling by invitation |
NCT04093570 -
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers
|
Phase 2 | |
Recruiting |
NCT04069208 -
IA14 Induction in Young Acute Myeloid Leukemia
|
Phase 2 | |
Recruiting |
NCT05744739 -
Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)
|
Phase 1 | |
Recruiting |
NCT04969601 -
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
|
Phase 1/Phase 2 |